Table 2.
Hydroxychloroquine and autoimmune disorders in pregnancy.
| Author and Year | Type of Study | Indication |
|---|---|---|
| Buchanan et al., (1996) [48] | Observational cohort | Systemic/discoid lupus erythematosus |
| Levy et al., (2001) [49] | Randomized control | Systemic/discoid lupus erythematosus |
| Costedoat-Chalumeau et al., (2003) [50] | Observational cohort | Systemic lupus erythematosus, Sjögren syndrome |
| Frassi et al., (2004) [51] | Observational cohort | Connective tissue disease |
| Clowse et al., (2006) [52] | Observational cohort | Systemic lupus erythematosus |
| Diav-Citrin et al., (2013) [53] | Observational cohort | Systemic lupus erythematosus, rheumatic arthritis, Behcet’s disease, Sjögren syndrome |
| Cooper et al., (2014) [54] | Observational cohort | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, scleroderma, inflammatory bowel disease |
| Gayed et al., (2014) [55] | Observational cohort | Systemic lupus erythematosus |
| Erkan et al., (2017) [56] | Observational cohort | Systemic lupus erythematosus |
| Izmirly P. et al., (2020) [26] | Randomized control | Prevention of fetal atrioventricular block for the fetus |
| Gerde M. et al., (2021) [57] | Observational cohort | Refractory obstetric antiphospholipid syndrome |
| Duan J. et al., (2021) [58] | Meta-analysis | Prophylaxis of preeclampsia, hypertension, and prematurity in pregnancies with SLE |
| Berard A. et al., (2012) [19] | Observational cohort | Treatment of SLE and rheumatoid arthritis |
| Beksac M.S. et al., (2021) [21] | Observational cohort | Autoimmune disorders, autoimmune antibody positivities, and chronic inflammatory/autoimmune diseases |
| Pasquier E. et al., (2019) [59] | Randomized placebo-controlled trial | Prevention of recurrent miscarriage |
| de Moreuil C. et al., (2020) [60] | Review of literature | Potential benefit in preeclampsia and recurrent miscarriage |